In the ongoing open-label, Phase 1B/2A trial currently underway at The University of Kansas Cancer Center, Notable is applying its high-fidelity predictive precision medicines platform with the goal of assessing patient responsiveness to fosciclopirox.
Under the terms of the co-development agreement, CicloMed holds the primary responsibility for executing clinical trial operations while Notable is primarily focused on optimizing Notable's predictive precision medicine platform.
Both parties will be responsible for the costs associated with the on-going clinical trial.
Fosciclopirox was discovered by scientists at The University of Kansas Cancer Center, a National Cancer Institute designated cancer center and the Institute for Advancing Medical Innovation, University of Kansas Medical Center's product development enterprise.
Fosciclopirox is part of an open-label, Phase 1B/2A study to characterize the efficacy, safety, PK, and pharmacodynamics of fosciclopirox administered alone and in combination with cytarabine in patients with relapsed or refractory AML.
CicloMed was formed in 2016 as a public-private partnership between BioNovus Innovations LLC and IAMI, with fosciclopirox as the partnership's lead drug development candidate.
CicloMed is a developmental-stage pharmaceutical company focusing on unmet medical needs in oncology, and fosciclopirox (formerly Ciclopirox Prodrug, CPX-POM) is its lead drug development candidate.
CicloMed is a portfolio company of BioNovus Innovations LLC, a unique venture formed to invest in individuals and organizations that are transforming healthcare.
BioNovus is charting a new path with the financial investment and commitment to bring novel solutions to reality.
Notable is a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, a new class of medicines.
Notable aims to be a leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatments that work best for them patient by patient, and cancer by cancer.
By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community.
Notable's proprietary predictive precision medicines platform bio-simulates a patient's cancer treatment and predicts whether a patient will respond to a specific cancer treatment.
Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population.
Notable has created a targeted, triple de-risked in-licensing strategy to deliver a product's medical impact and commercial value faster, higher, and more likely than traditional drug development.
Investors in Notable include B Capital Group, Lifeforce Capital, Builders VC, Founders Fund, Lightspeed Venture Partners, Y Combinator, First Round Capital as well as 11.2 Capital, Refactor Capital, Upside Partnership, and Fuel Ventures.
Notable is headquartered in Foster City, California.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories